Acetaminophen (
APAP) hepatotoxicity remains the leading cause of
drug-induced liver injury due to the lack of safe and effective therapeutic agents.
Berberine (BBR) is a natural
alkaloid derived from
traditional medicine Rhizoma Coptidis and possesses various pharmacological properties. The aim of this study was to explore the hepatoprotective effects and underlying mechanisms of BBR on
APAP-induced hepatotoxicity. Our results indicated that BBR pretreatment significantly ameliorated
APAP-induced hepatic pathological abnormalities and attenuated the elevations of serum
aminotransferases and liver/
body weight ratio. Compared to
APAP group, BBR notably increased the levels of hepatic
UDP-glucuronosyltransferases and
sulfotransferases, whereas failed to ameliorate
APAP-induced GSH depletion. Pretreatment with BBR significantly reduced hepatic MDA and MPO levels, inhibited JNK phosphorylation and up-regulated the expression of nuclear Nrf-2 and its downstream gene
Mn-SOD. Additionally, BBR obviously prevented
APAP-induced DNA fragmentation. Furthermore, BBR pretreatment dramatically reduced the expression of pro-inflammatory
cytokines,
HMGB1, p-p65 and cleaved caspase-1 and inhibited the infiltration of macrophages and neutrophils. Taken these results together, BBR exhibits notable preventive effects on
APAP-induced hepatotoxicity by inhibiting oxidative stress, hepatocyte
necrosis and inflammatory response.